How this biotech nearly tripled its IPO price with a buyout in less than 4 months
May 10, 2018 at 11:22 AM EDT
Pharma giant Eli Lilly and Co. will buy small cancer immunotherapy drug developer ARMO BioSciences Inc., a Redwood City company that went public in January, in a $1.6 billion all-cash deal.
